Systematic review and meta-analysis evaluating the efficacy and safety of novel-agent–based frontline regimens (Brentuximab Vedotin and PD-1 inhibitors) in patients aged ≥ 60 years with classical Hodgkin lymphoma (cHL), pooling data from 11 studies (n=568).
Pooled complete response (CR) rate was 71% (95% CI: 57–81%) and pooled 2-year PFS was 66% (95% CI: 45–83%). In indirect subgroup comparisons, nivolumab-based regimens showed higher response rates and PFS than BV-based regimens, with lower rates of treatment discontinuation, Grade ≥ 3 infections, and neuropathy.
- All comparisons between nivolumab- and BV-based regimens are indirect, with marked heterogeneity across studies. - Only 11 studies with 568 patients were included, likely reflecting the underrepresentation of older adults in clinical trials. - Differences in outcomes may reflect study design and patient selection rather than true treatment effects.
Novel-agent–based frontline regimens offer better efficacy and tolerability than traditional chemotherapy in older adults (≥60) with cHL. Nivolumab-based regimens appear to be a particularly favorable option, but direct comparative trials are needed before firm preference recommendations can be made.
Explore related topics
